Atlas Trials

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Clinical trial NCT06319170 · COMPLETED

Trial details

NCT number
NCT06319170
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia, Schizoaffective Disorder
Start date
2024-03-28
Primary completion
2025-01-15
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.